Receive alerts
Market Cap:
52 weeks high
52 weeks low

In brief

Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines.  Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering.  We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue.

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Redx Pharma hopes Astra deal will shine light on fibrosis treatments

Fibrosis can be anywhere in the body, not only the lungs: it’s also found in the liver, kidneys, brain and heart

on 5/8/20